Drugs / PF-00217830
last change Sep 2008 re-read 2 minutes ago

PF-00217830

also known as J2.975.999E · PF-217830

Small molecule targets DRD2 via activation

Developed for
schizophrenia
Investigated by
Pfizer

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00580125 Nov 2007 → Sep 2008 schizophrenia Pfizer Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as PF-00217830 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00580125
Known as J2.975.999E ChEMBL registry synonym — accepted as the source's own label CHEMBL1774080
Known as PF-217830 ChEMBL registry synonym — accepted as the source's own label CHEMBL1774080
Action Activate “Dopamine D2 receptor partial agonist” CHEMBL1774080
Modality Small molecule CHEMBL1774080
Route Oral oral capsule” NCT00580125
Target DRD2 “Dopamine D2 receptor partial agonist” CHEMBL1774080